மருத்துவ ஆராய்ச்சி சேவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ ஆராய்ச்சி சேவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ ஆராய்ச்சி சேவை Today - Breaking & Trending Today

Partnering up with Abiraterone Acetate – Potentials for a Harmonious Relationship


Partnering up with Abiraterone Acetate – Potentials for a Harmonious Relationship
Published 03 May 2021
Abiraterone acetate has demonstrated benefit across the metastatic prostate cancer spectrum when combined or layered on conventional androgen deprivation therapy. Whether it be metastatic castration-sensitive (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC) in either the pre-or the post-docetaxel setting, the overall survival benefit is certain.
1-4 Attempts to advance to the next level with additional agents added to abiraterone acetate, in the first-line mCRPC setting, have been met with mixed results. At this time, other than the continuing foundation of androgen deprivation therapy, there is no therapeutic agent regulatory approved for combination with abiraterone acetate. ....

United States , Fred Hutchinson Cancer Research Center , University Of Washington , Evan Yu , Clinical Research Division , Clinical Research Service , Prostate Cancer Clinical Research , Seattle Cancer Care Alliance , Fred Hutchinson Cancer Research Consortium , University Of Washington School Medicine , Clinical Research , Division Of Oncology , Department Of Medicine , Washington School , Clinical Research Director , Genitourinary Oncology , Medical Director , Randomized Phase , Sequential Abiraterone Acetate , Metastatic Castration Resistant Prostate Cancer , ஒன்றுபட்டது மாநிலங்களில் , ஃப்ரெட் ஹட்சின்சன் புற்றுநோய் ஆராய்ச்சி மையம் , பல்கலைக்கழகம் ஆஃப் வாஷிங்டன் , எவன் யூ , மருத்துவ ஆராய்ச்சி பிரிவு , மருத்துவ ஆராய்ச்சி சேவை ,

Is Adjuvant Therapy a New Standard for Urothelial Carcinoma?


Published 01 April 2021
Adjuvant therapy trials for urothelial carcinoma have traditionally been challenging to perform.  Radical cystectomy is a significantly morbid procedure that leads to high complication and readmission rates.   Hence, many patients are not fit to receive any adjuvant therapy after definitive local therapy due to a compromised health situation. At this time, neoadjuvant chemotherapy is still the definitive standard.
1 However, not all patients receive neoadjuvant therapy for a multitude of reasons.  For those who did not receive neoadjuvant cisplatin combination chemotherapy, common sense warrants strong consideration of adjuvant therapy as long as a patient is fit and interested.
However, we have extremely limited evidence on what to do if a patient has residual muscle invasive disease after prior receipt of neoadjuvant combination cisplatin-based chemotherapy.  This is clearly an unmet need population due to the very poor prognosis. ....

Fred Hutchinson Cancer Research Center , United States , University Of Washington , Comunidad Autonoma De Cataluna , Evan Yu , Clinical Research Division , Clinical Research Service , Spanish Oncology Genitourinary Group , Seattle Cancer Care Alliance , Clinical Research , Fred Hutchinson Cancer Research Consortium , University Of Washington School Medicine , Division Of Oncology , Department Of Medicine , Advanced Bladder Cancer , Therapy Trials , High Risk Urothelial , Washington School , Clinical Research Director , Genitourinary Oncology , Medical Director , Cystectomy Compared , Cystectomy Alone , Locally Advanced Bladder Cancer , Eur Urol , ஃப்ரெட் ஹட்சின்சன் புற்றுநோய் ஆராய்ச்சி மையம் ,